据报FDA即将批准紧急使用Moderna疫苗
外电消息指,美国食品药品监督管理局(FDA)将於未来数天,批准紧急使用Moderna疫苗。
FDA负责人Stephen Hahn已於周四通知Moderna,当局正在为紧急批准公司疫苗作出最後修订,并正在为医护人员制作指引。
一旦完成後,美国将成为首个国家同时批准使用辉瑞/BioNTech和Moderna疫苗的国家。
Moderna疫苗的成功率为94.1%,与辉瑞/BioNTech相同,但前者只准许18岁或以上人士接种,而後者则为16岁或以上。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.